What is Roth Capital’s Forecast for OptimizeRx Q1 Earnings?

OptimizeRx Co. (NASDAQ:OPRX) – Research analysts at Roth Capital issued their Q1 2026 earnings estimates for OptimizeRx in a research report issued to clients and investors on Wednesday, March 12th. Roth Capital analyst R. Baldry anticipates that the company will post earnings per share of ($0.19) for the quarter. The consensus estimate for OptimizeRx’s current full-year earnings is ($0.33) per share. Roth Capital also issued estimates for OptimizeRx’s Q2 2026 earnings at ($0.16) EPS, Q3 2026 earnings at ($0.05) EPS and Q4 2026 earnings at $0.44 EPS.

A number of other equities analysts have also recently issued reports on the company. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 target price on shares of OptimizeRx in a report on Thursday, February 6th. B. Riley raised shares of OptimizeRx to a “strong-buy” rating in a report on Wednesday, March 12th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $6.00 price target (down previously from $7.00) on shares of OptimizeRx in a research note on Wednesday, January 8th. Lake Street Capital reaffirmed a “buy” rating and set a $11.00 target price on shares of OptimizeRx in a research report on Tuesday, December 24th. Finally, Stephens assumed coverage on OptimizeRx in a research report on Friday, December 20th. They issued an “equal weight” rating and a $5.50 price target on the stock. Three equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, OptimizeRx currently has a consensus rating of “Moderate Buy” and an average price target of $9.06.

OptimizeRx Stock Up 6.4 %

Shares of OPRX opened at $8.27 on Monday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23. OptimizeRx has a 52 week low of $3.78 and a 52 week high of $14.13. The stock has a market capitalization of $152.34 million, a price-to-earnings ratio of -6.22 and a beta of 1.31. The stock has a fifty day moving average of $5.58 and a 200-day moving average of $5.90.

Hedge Funds Weigh In On OptimizeRx

Several institutional investors have recently added to or reduced their stakes in the business. Janney Montgomery Scott LLC bought a new stake in shares of OptimizeRx in the 3rd quarter valued at $810,000. Quest Partners LLC increased its stake in OptimizeRx by 15,965.6% in the third quarter. Quest Partners LLC now owns 9,800 shares of the company’s stock valued at $76,000 after purchasing an additional 9,739 shares in the last quarter. BNP Paribas Financial Markets raised its holdings in shares of OptimizeRx by 189.2% during the third quarter. BNP Paribas Financial Markets now owns 3,690 shares of the company’s stock valued at $28,000 after purchasing an additional 2,414 shares during the period. Barclays PLC boosted its position in shares of OptimizeRx by 358.5% during the 3rd quarter. Barclays PLC now owns 26,934 shares of the company’s stock worth $208,000 after purchasing an additional 21,060 shares in the last quarter. Finally, Bullseye Asset Management LLC grew its stake in shares of OptimizeRx by 55.6% in the 3rd quarter. Bullseye Asset Management LLC now owns 214,046 shares of the company’s stock valued at $1,652,000 after buying an additional 76,458 shares during the period. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.